1. Protein Tyrosine Kinase/RTK
  2. c-Kit

c-Kit

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.

c-Kit Related Products (23):

Cat. No. Product Name Effect Purity
  • HY-10201
    Sorafenib Inhibitor 99.83%
    Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-16749
    Pexidartinib Inhibitor 98.86%
    Pexidartinib(PLX-3397) is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
  • HY-10201A
    Sorafenib Tosylate Inhibitor 99.73%
    Sorafenib tosylate is a potent multikinase inhibitor, with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-13016
    Cabozantinib Inhibitor 99.92%
    Cabozantinib is a potent multiple RTKs inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-50946
    Imatinib Mesylate Inhibitor 99.90%
    Imatinib Mesylate is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kit wt kinase with IC50 of ~100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.
  • HY-10228
    Motesanib Inhibitor 99.93%
    Motesanib is a potent ATP-competitive inhibitor of?VEGFR1/2/3?with?IC50s?of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.
  • HY-101443
    ISCK03 Inhibitor 98.82%
    ISCK03 is a specific SCF/c-Kit inhibitor.
  • HY-15463
    Imatinib Inhibitor 99.93%
    Imatinib is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kitwt kinase with IC50 of ~100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.
  • HY-10208
    Pazopanib Inhibitor 99.44%
    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-50905
    Dovitinib Inhibitor 99.31%
    Dovitinib is a multitargeted RTK inhibitor, and inhibits FGFR3 with IC50 of 5 nM.
  • HY-10209
    Masitinib Inhibitor 99.92%
    Masitinib(AB-1010) is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
  • HY-12009
    Pazopanib Hydrochloride Inhibitor 99.92%
    Pazopanib Hcl (GW-786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.
  • HY-15240
    DCC-2618 Inhibitor 99.04%
    DCC-2618 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM.
  • HY-15002
    AST 487 Inhibitor 98.64%
    AST487(NVP-AST487) is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.
  • HY-10527
    Telatinib Inhibitor 98.54%
    Telatinib(Bay 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively.
  • HY-10206
    Amuvatinib Inhibitor 99.84%
    Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.
  • HY-13838
    PLX647 Inhibitor
    PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.
  • HY-16961
    Sitravatinib Inhibitor 98.64%
    Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/L
  • HY-10204
    OSI-930 Inhibitor 99.82%
    OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.
  • HY-10229
    Motesanib Diphosphate Inhibitor
    Motesanib diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret.